# US 2021/0277364 A1 · Scalable purification method for aav8

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277364 A1
- Document ID: US20210277364A1
- Status: Published application
- Kind: A1
- Application number: 17/328,686
- Filed: 2021-05-24
- Published: 2021-09-09
- Earliest claimed: 2015-12-11
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Martin Lock; Mauricio Alvira
- Web page: https://patentgrep.com/patent/US20210277364A1

## CPC

- C12N 7/02: Recovery or purification
- B01D 15/363: {Anion-exchange}
- B01D 15/3804: {Affinity chromatography}
- B01J 20/281: Sorbents specially adapted for preparative, analytical or investigative chromatography
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 15/8645: {Adeno-associated virus}
- G01N 21/33: using ultraviolet light (G01N21/39 takes precedence)
- B01D 15/166: {Fluid composition conditioning, e.g. gradient}
- B01J 41/05: in the strongly basic form
- B01J 41/20: Anion exchangers for chromatographic processes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14151: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.

## Claims

### Claim 1

A method for separating AAV8 viral particles having packaged genomic sequences from genome-deficient AAV8 capsid intermediates, said method comprising:
subjecting a mixture comprising recombinant AAV8 viral particles and AAV8 capsid intermediates to fast performance liquid chromatography, wherein the AAV8 viral particles and AAV8 intermediates are bound to an anion exchange resin equilibrated at a pH of about 10.2 and subjected to a salt gradient while monitoring eluate for ultraviolet absorbance at about 260 and about 280, wherein the AAV8 full capsids are collected from a fraction which is eluted when the ratio of A260/A280 reaches an inflection point.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the inflection point is when the curve ratio of A260/A280 changes from less than 1 to greater than 1.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the salt gradient has an ionic strength equivalent to at least about 20 mM to about 190 mM NaCl.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the AAV8 intermediates are eluted from the anion exchange resin when the salt gradient reaches an ionic strength equivalent to about 50 nM NaCl or greater.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the mixture comprising the recombinant AAV8 viral particles and AAV8 capsid intermediates contains less than about 10% contamination from viral and cellular proteinaceous and nucleic acid materials.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the mixture is at least about 95% purified from viral and cellular proteinaceous and nucleic acid materials.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the method has a sample loading flow rate less than or equal to the elution flow rate.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the anion exchange resin is a strong resin.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the anion exchange resin is in a column.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the mixture comprising recombinant AAV8 viral particles and AAV8 capsid intermediates had been purified from production system contaminants using affinity capture.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the affinity capture is performed using an affinity resin.

### Claim 12

A method for separating AAV8 viral particles from AAV8 capsid intermediates, said method comprising:
(a) mixing a suspension comprising recombinant AAV8 viral particles and AAV8 capsid intermediates and a Buffer A having a pH of about 10.2;
(b) loading the suspension of (a) onto a strong anion exchange resin column;
(c) washing the loaded anion exchange resin with Buffer 1% B which comprises a salt having and a pH of about 10.2;
(d) applying an increasing salt concentration gradient to the loaded and washed anion exchange resin, wherein the salt gradient is sufficient to elute the rAAV8 particles; and
(e) collecting rAAV8 particles which are at least about 90% purified from AAV8 intermediates.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the recombinant AAV8 viral particles and AAV8 capsid of step (a) have been affinity purified at a high salt concentration.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the anion exchange resin is a quaternary amine ion exchange resin.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the anion exchange resin column comprises trimethylamine and a support matrix comprising poly(glycidyl methacrylate-co-ethylene dimethacrylate).

### Claim 16 (depends on 12)

The method according to claim 12, wherein Buffer A is further admixed with NaCl to a final concentration of 1M in order to form or prepare Buffer B.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the salt gradient is from about 10 mM to about 190 mM NaCl or a salt equivalent.

### Claim 18 (depends on 12)

The method according to claim 12, wherein the elution gradient is from 1% buffer B to about 19% Buffer B.

### Claim 19 (depends on 12)

The method according to claim 12, wherein when the anion exchange resin column is a monolith column and where column loading, washing, and elution occur in about 60 column volumes.

### Claim 20 (depends on 12)

The method according to claim 12, wherein the elution flow rate is from about 10 mL/min to about 40 mL/min.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the elution flow rate is about 20 mL/min.

### Claim 22

A method for separating recombinant AAV8 viral particles containing DNA comprising pharmacologically active genomic sequences from genome-deficient (empty) AAV8 capsid intermediates, said method comprising:
(a) forming a loading suspension comprising:
recombinant AAV8 viral particles and empty AAV8 capsid intermediates which have been purified to remove non-AAV materials from an AAV producer cell culture in which the particles and intermediates were generated; and a Buffer A comprising 20 mM Bis-Tris propane (BTP) and a pH of about 10.2;
(b) loading the suspension of (a) onto a strong anion exchange resin, said resin being in a vessel having an inlet for flow of a suspension and/or solution and an outlet permitting flow of eluate from the vessel;
(c) washing the loaded anion exchange resin with Buffer 1% B which comprises 10 mM NaCl and 20 mM BTP with a pH of about 10.2;
(d) applying an increasing salt concentration gradient to the loaded and washed anion exchange resin, wherein the salt gradient ranges from 10 mM to about 190 mM NaCl, inclusive of the endpoints, or an equivalent; and
(e) collecting the rAAV particles from eluate, said rAAV particles being purified away from 9 intermediates.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the pH is 10.2 and the rAAV particles are at least about 90% purified from AAV8 intermediates.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the average yield of rAAV particles is at least about 40% to about 70% as measured by GC titer.

### Claim 25 (depends on 22)

The method according to claim 22, wherein the producer cell culture is selected from a mammalian cell culture, a bacterial cell culture, and an insect cell culture, wherein said producer cells comprise at least (i) nucleic acid sequence encoding an AAV8 capsid operably linked to sequences which direct expression of the AAV8 capsid in the producer cells; (ii) a nucleic acid sequence comprising AAV inverted terminal repeat sequences and genomic transgene sequences for packaging into the AAV8 capsid; and (iii) functional AAV rep sequences operably linked to sequences which direct expression thereof in the producer cells.

### Claim 26 (depends on 22)

The method according to claim 22, wherein material harvested from the cell culture is applied to an affinity resin to separate contaminants from AAV8 viral particles and empty AAV8 capsid intermediates.
